New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
February 4, 2014
10:00 EDTHK, FRX, AWI, WETF, NLSN, GPS, DVN, ANGI, ORLY, PFE, MRK, FRC, CVX, AGN, ZNGA, OPEN, GILD, DRE, CBT, OIS, CRMOn the Fly: Analyst Upgrade Summary
Allergan (AGN) upgraded to Buy from Neutral at Citigroup... Angie's List (ANGI) upgraded to Outperform from Market Perform at Barrington... Cabot (CBT) upgraded to Buy from Neutral at SunTrust... Chevron (CVX) upgraded to Strong Buy from Outperform at Raymond James... Devon Energy (DVN) upgraded to Outperform from Neutral at Credit Suisse... Duke Realty (DRE) upgraded to Outperform from Sector Perform at RBC Capital... First Republic (FRC) upgraded to Outperform from Market Perform at Keefe Bruyette,,, Gap (GPS) upgraded to Buy from Neutral at UBS... Gilead (GILD) upgraded to Outperform from Neutral at RW Baird... Merck (MRK) upgraded to Buy from Neutral at SunTrust... Nielsen (NLSN) upgraded to Buy from Hold at Pivotal Research... OpenTable (OPEN) upgraded to Neutral from Sell at Citigroup... Pfizer (PFE) upgraded to Buy from Hold at Jefferies... Salesforce.com (CRM) upgraded to Buy from Neutral at Roth Capital... Zynga (ZNGA) upgraded to Buy from Neutral at UBS... O'Reilly Automotive (ORLY) upgraded to Buy from Neutral at Northcoast... Oil States (OIS) upgraded to Buy from Accumulate at Tudor Pickering... Armstrong World (AWI) upgraded to Buy from Hold at Gabelli... Halcon Resources (HK) upgraded to Neutral from Reduce at Global Hunter... Wisdom Tree (WETF) upgraded to Buy from Neutral at BofA/Merrill... Forest Labs (FRX) upgraded to Overweight from Neutral at JPMorgan.
News For AGN;ANGI;CBT;CVX;DVN;DRE;FRC;GPS;GILD;MRK;NLSN;OPEN;PFE;CRM;ZNGA;ORLY;OIS;AWI;HK;WETF;FRX From The Last 14 Days
Check below for free stories on AGN;ANGI;CBT;CVX;DVN;DRE;FRC;GPS;GILD;MRK;NLSN;OPEN;PFE;CRM;ZNGA;ORLY;OIS;AWI;HK;WETF;FRX the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 | all recent news | >>
April 10, 2014
17:44 EDTMRKMerck stock could return 20%, Barron's says
Subscribe for More Information
16:06 EDTZNGAZynga CFO Vranesh leaving company, Best Buy's Lee to succeed as CFO
Subscribe for More Information
16:02 EDTGPSGap reaffirms FY14 EPS view $2.90-$2.95, consensus $2.96
As the company noted last month, the Easter holiday is in April this year versus March last year. Given this shift in peak spring selling weeks, the company expected March to be negatively impacted. The company expects gross margins for Q1 to be below the prior year by more than the year-over-year decline in Q4. In addition, given ongoing expense management, the company expects Q1 operating expenses to be flat to last year.
16:01 EDTGPSGap reports March SSS down 6%
Subscribe for More Information
13:12 EDTGILDGilead volatility increases on wide price movement
Subscribe for More Information
12:46 EDTCVXChevron management to meet with Jefferies
Meetings to be held in London on April 16-17 hosted by Jefferies.
11:44 EDTGILDStocks with call strike movement; PCLN GILD
Subscribe for More Information
11:42 EDTGILDReport claims Tamiflu, Relenza do little to prevent the spread of flu
Subscribe for More Information
09:37 EDTCVX, MRKActive equity options trading on open
Active equity options trading on open according to Track Data: SIRI RAD AAPL AMZN AA FB TSLA MRK CVX C
09:21 EDTMRKOn The Fly: Pre-market Movers
Subscribe for More Information
09:02 EDTCVXChevron, YPF continue development of Vaca Muerta Shale in Argentina
Subscribe for More Information
09:01 EDTCRMSalesforce.com should be bought ahead of results, says Pacific Crest
Subscribe for More Information
08:03 EDTMRKXencor Merck receives milestone payment from Merck for using XmAb antibody
Xencor (XNCR) announced that the company has received a milestone payment from Merck (MRK), through a subsidiary, triggered by the initiation of a Phase 1 clinical trial for an undisclosed biologic drug candidate that uses Xencor's XmAb antibody engineering intellectual property. Under the terms of the agreement signed in June 2013, Xencor granted Merck a non-exclusive license to certain Xencor patents for use in an undisclosed product, as well as an option to license the same intellectual property for future products. Xencor received an upfront payment and continues to receive annual maintenance fees. Xencor is also eligible to receive milestone payments associated with the successful development of Merck product candidates, as well as royalties on sales of any potential products that may result from this agreement.
07:24 EDTGILDInternational Society for Heart & Lung Transplantation to hold annual meeting
Subscribe for More Information
07:13 EDTDVNAnadarko and Devon midstream assets underappreciated, says Credit Suisse
Subscribe for More Information
06:17 EDTPFEAcura Pharma announces return of product rights from Pfizer
Subscribe for More Information
06:03 EDTHKStocks with implied volatility movement; KOG HK
Subscribe for More Information
05:37 EDTGILDGilead announces Phase 2 results for investigational sofosbuvir-based regimens
Gilead Sciences announced data from two Phase 2 studies evaluating investigational all-oral regimens containing the nucleotide analog polymerase inhibitor sofosbuvir, or SOF, for the treatment of chronic hepatitis C virus, or HCV, infection. The first study, ELECTRON2, is an ongoing, open-label Phase 2 clinical trial evaluating a once-daily fixed-dose combination of SOF 400 mg and the NS5A inhibitor ledipasvir, or LDV, 90 mg, with and without ribavirin, or RBV, twice-daily, among HCV-infected patient populations. In this study, 100% of treatment-na´ve genotype 3 patients receiving 12 weeks of LDV/SOF plus RBV and 64% of treatment-na´ve genotype 3 patients receiving 12 weeks of LDV/SOF without RBV achieved a sustained virologic response 12 weeks after completing therapy. Among genotype 1-infected patients who had failed prior treatment with SOF plus RBV, 100% achieved SVR12 following 12 weeks of LDV/SOF plus RBV. Additionally, 65% of genotype 1-infected patients with decompensated or Child-Turcotte-Pugh Class B cirrhosis receiving 12 weeks of LDV/SOF without RBV achieved SVR12. LDV/SOF with and without RBV was well-tolerated, including among patients with more advanced liver disease. A second study, Study GS-US-342-0102, is an ongoing randomized Phase 2 clinical trial in which treatment-na´ve, non-cirrhotic patients with genotypes 1-6 HCV infection received a 12-week course of SOF plus the pan-genotypic NS5A inhibitor GS-5816. Patients received SOF 400 mg and either GS-5816 25 mg or GS-5816 100 mg. In this study, 94.8% of patients receiving the 25 mg dose of GS-5816 and 96.1% of patients receiving the 100 mg dose achieved SVR12.
05:32 EDTGILDGilead announces results from study of Sovaldi
Subscribe for More Information
05:27 EDTMRKMerck announces data from C-WORTHy study
Merck announced additional data from the ongoing C-WORTHy study, a multi-arm Phase 2 clinical trial evaluating the efficacy and safety of a once-daily, all-oral regimen combining MK-5172, an investigational hepatitis C virus, or HCV, NS3/4A protease inhibitor, and MK-8742, an investigational HCV NS5A replication complex inhibitor, among patients with chronic HCV Genotype 1 infection, or GT1. In an interim analysis of treatment-na´ve, non-cirrhotic patients administered a 12-week regimen of MK-5172/MK-8742, with and without ribavirin, or RBV, a sustained viral response, or SVR, was observed in 98% of patients administered MK-5172/MK-8742 alone and 94% in those administered MK-5172/MK-8742 plus RBV.
1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use